These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16323435)

  • 1. Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003.
    Sader HS; Fritsche TR; Streit JM; Jones RN
    J Chemother; 2005 Oct; 17(5):477-83. PubMed ID: 16323435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):417-22. PubMed ID: 23514757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS; Watters AA; Fritsche TR; Jones RN
    BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
    Sader HS; Farrell DJ; Jones RN
    J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007).
    Sader HS; Moet G; Jones RN
    J Chemother; 2009 Nov; 21(5):500-6. PubMed ID: 19933040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 May; 43(5):465-9. PubMed ID: 24636430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
    Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
    Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).
    Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):158-62. PubMed ID: 19748426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2004 Nov; 50(3):201-4. PubMed ID: 15541606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece.
    Malli E; Spiliopoulou I; Kolonitsiou F; Klapsa D; Giannitsioti E; Pantelidi K; Pratti A; Panopoulou M; Grapsa S; Alepopoulou E; Neonakis I; Frantzidou F; Alexiou-Daniel S; Bakola D; Koutsia-Carouzou C; Malamou-Lada H; Zerva L; Vlahaki E; Kartali-Ktenidou S; Anastassiou ED; Petinaki E
    Int J Antimicrob Agents; 2008 Dec; 32(6):525-8. PubMed ID: 18774268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006).
    Castanheira M; Jones RN; Sader HS
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):235-9. PubMed ID: 18314293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.
    Streit JM; Jones RN; Sader HS
    J Antimicrob Chemother; 2004 Apr; 53(4):669-74. PubMed ID: 14985278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
    Fritsche TR; Sader HS; Stillwell MG; Jones RN
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005).
    Pfaller MA; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):459-65. PubMed ID: 17240105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
    Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
    J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of occurrence and daptomycin susceptibility rates of Gram-positive organisms causing bloodstream infections in cancer patients.
    Sader HS; Fritsche TR; Jones RN
    J Chemother; 2008 Oct; 20(5):570-6. PubMed ID: 19028618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008).
    Bell JM; Turnidge JD; Sader HS; Jones RN
    Pathology; 2010; 42(5):470-3. PubMed ID: 20632825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.